Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Public Relations Changes Continue; Bello Overseeing Communications

Executive Summary

The Pharmaceutical Research & Manufacturers of America's communications staff will be overseen by Judy Bello during the search for a new VP

You may also be interested in...



PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

PhRMA Readies “Access & Affordability” Campaign; PR Overhaul Complete

The Pharmaceutical Research & Manufacturers of America is establishing an internal group on drug access and affordability in preparation for launching a nationwide public educational effort on the theme

PhRMA Close To Deal With Tauzin; Changes In Reg Affairs, PR Line Up

The Pharmaceutical Research & Manufacturers of America is understood to be close to finalizing an agreement with Rep. Billy Tauzin (R-La.) to take over as the new CEO of the trade group

Related Content

UsernamePublicRestriction

Register

PS043046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel